Immune-Onc Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IO-202 / Immune-Onc Therap
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Completed
1
67
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/25
01/25
NCT05309187: Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Completed
1
22
US
IO-202, IO-202 + pembrolizumab combination therapy, IO-202 + Keytruda combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types, RP2D of IO-202 + Keytruda combination therapy
Immune-Onc Therapeutics
Solid Tumor, Adult
03/24
05/24
IO-108 / Immune-Onc Therap
Morpheus-Liver, NCT04524871 / 2020-001743-10: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers

Recruiting
1/2
518
Europe, US, RoW
Atezolizumab, Tecentriq, Bevacizumab 15 mg/kg, Avastin, Tiragolumab, Tocilizumab, Actemra, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg
Hoffmann-La Roche, Adagene Inc, Tempest Therapeutics, NiKang Therapeutics, Inc., Immune-Onc Therapeutics
Advanced Liver Cancers
12/26
12/26
IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed
1
91
US
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy
Immune-Onc Therapeutics, Regeneron Pharmaceuticals
Solid Tumor, Adult
04/24
05/24
NCT05508100: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Completed
1
38
RoW
IO-108, IO-108 + pembrolizumab, IO-108 + Keytruda®, IO-108 + tislelizumab
Immune-Onc Therapeutics
Advanced Solid Tumor
04/24
04/24
LILRB4 targeted CAR-T / Immune-Onc Therap
No trials found
IO-106 / Immune-Onc Therap
No trials found
IO-312 / Immune-Onc Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IO-202 / Immune-Onc Therap
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Completed
1
67
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/25
01/25
NCT05309187: Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Completed
1
22
US
IO-202, IO-202 + pembrolizumab combination therapy, IO-202 + Keytruda combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types, RP2D of IO-202 + Keytruda combination therapy
Immune-Onc Therapeutics
Solid Tumor, Adult
03/24
05/24
IO-108 / Immune-Onc Therap
Morpheus-Liver, NCT04524871 / 2020-001743-10: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers

Recruiting
1/2
518
Europe, US, RoW
Atezolizumab, Tecentriq, Bevacizumab 15 mg/kg, Avastin, Tiragolumab, Tocilizumab, Actemra, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg
Hoffmann-La Roche, Adagene Inc, Tempest Therapeutics, NiKang Therapeutics, Inc., Immune-Onc Therapeutics
Advanced Liver Cancers
12/26
12/26
IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed
1
91
US
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy
Immune-Onc Therapeutics, Regeneron Pharmaceuticals
Solid Tumor, Adult
04/24
05/24
NCT05508100: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Completed
1
38
RoW
IO-108, IO-108 + pembrolizumab, IO-108 + Keytruda®, IO-108 + tislelizumab
Immune-Onc Therapeutics
Advanced Solid Tumor
04/24
04/24
LILRB4 targeted CAR-T / Immune-Onc Therap
No trials found
IO-106 / Immune-Onc Therap
No trials found
IO-312 / Immune-Onc Therap
No trials found

Download Options